A Phase 1 interventional study of PST-611 in Dry Age Related Macular Degeneration, sponsored by Eyevensys. Completed at 2 sites in France. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-07-13.
Sponsored by Eyevensys · Phase 1, Interventional, and Treatment
Among 120 studies in Macular Degeneration with a site in France — 27 open to participants now, 34 under way, 8 of them phase 3. Macular Degeneration · France.
Among the 120 studies in Macular Degeneration with a site in France, this one is the 83rd largest by enrollment of the 84 interventional ones, is one of 12 that started in 2025, is one of 2 in phase 1, and was the 113th registered.
1,459 studies on the registry are indexed under Macular Degeneration; 238 are open to participants now.
This study's enrollment of 8 is below the median of 56 across 985 interventional studies indexed under Macular Degeneration.
Browse Macular Degeneration studies →27 of the 120 studies in Macular Degeneration with a site in France are open now, in 12 countries. Each count lists the studies.
Of the 165 Macular Degeneration studies recruiting now, 116 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →120 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 12 started in 2025.
Median enrollment 249 across the 84 interventional studies, 219 across the 36 observational. Of the 79 that completed or were terminated, 35 (44%) have results posted.
67 of 120 have an industry lead sponsor. The 10 most frequent:
Eyevensys is the lead sponsor of 4 studies on the registry; 1 is open to participants now.
Eyevensys has 2 studies filed under Macular Degeneration — fewer than ten, so there is no comparison to draw.
10 of the studies in Macular Degeneration with a site in France that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04657289Phase 3Hoffmann-La RocheA Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome) | 2027-02-04 |
| NCT07064759Phase 34D Molecular TherapeuticsSingle Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration | 2027-11 |
| NCT07164378VisionCare, Inc.International Study of the SING IMT™ Prosthesis in Pseudophakic patiEnts With Stable Moderate to Profound Bilateral Central vIsion Impairment Due to adVancEd AMD / PERSPECTIVE Study | 2026-12-30 |
| NCT04439708Institut National de la Santé Et de la Recherche Médicale, FranceBiomarkers and Choroidal Neovascularization | 2027-01-06 |
| NCT04292080Assistance Publique - Hôpitaux de ParisLong-Term Analysis of DImethyl Fumarate, to Slow the Growth of Areas of Geographic Atrophy | 2027-04-07 |
Among the 120 studies in Macular Degeneration with a site in France, from their registry updates:
The goal of this interventional study is to evaluate the safety and tolerability of single ascending doses of PST-611 in men and women over the age of 50 with dry age-related macular degeneration (AMD).
The main question it aims to answer is: Is PST-611-CT1 safe for participants?
Participants will:
The maximum study duration per patient is 28 Weeks (including an up to 12 week screening period + 16 weeks of follow-up after treatment).
The study is a single ascending dose study that investigates two PST-611 dose levels (low and high doses) in 2 successive dose groups. The study will enroll up to 12 participants.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
- Both eyes: any active intraocular or periocular infection or inflammation (eg, infectious blepharitis, infectious conjunctivitis, keratitis, scleritis, endophthalmitis), or history of intraocular or periocular infection or inflammation in the 12 weeks (84 days) prior to the PST-611 administration.
Study eye: Any intraocular surgery (including cataract surgery) or intravitreal (IVT) or periocular injection within 12 weeks (84 days) prior to the PST-611 administration.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This arm consists of 2 dose groups receiving a single ascending dose of PST-611. These groups will be dosed sequentially, low dose followed by high dose.
Biological: PST-611
PST-611 is a naked plasmid DNA encoding human transferrin administered into the ciliary muscle
Safety and Tolerability
Ocular and non-ocular adverse events frequency and severity
Time frame: Screening to week 16
Intraocular pressure
Intraocular pressure measured in mmHg
Time frame: Screening to Week 16
Best corrected visual acuity
Best corrected visual acuity measured in ETDRS letters
Time frame: Screening to Week 16
Slit lamp biomicroscopy examination
Abnormal examination results will be recorded
Time frame: Screening to Week 16
Dilated ophthalmoscopy examination
Abnormal examination results will be recorded
Time frame: Screening to Week 16
Color fundus photography
Abnormal findings will be recorded
Time frame: Screening to Week 16
Spectral Domain-Optical Coherence Tomography
Abnormal findings will be recorded
Time frame: Screening to Week 16
Plan to share: No
Ran from Jun 2025 to primary completion in Apr 2026, 9 months.
Of 60 industry-sponsored phase 1 interventional studies under Macular Degeneration, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 27. This study's 9 months is below that.
Counting every sponsor, half of 75 studies reached it within 18 months; a quarter within 10 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Eyevensys